We are analyzing https://link.springer.com/article/10.1186/s13058-015-0661-5.

Title:
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers | Breast Cancer Research
Description:
Despite significant advances in early detection and treatment, breast cancer still remains a major cause of morbidity and mortality for women. Our understanding of the molecular heterogeneity of the disease has significantly expanded over the past decade and the role of cell cycle signaling in both breast cancer oncogenesis and anti-estrogen resistance has gained increasing attention. The mammalian cell cycle is driven by a complex interplay between cyclins and their associated cyclin-dependent kinase (CDK) partners, and dysregulation of this process is one of the hallmarks of cancer. Despite this, initial results with broadly acting CDK inhibitors were largely disappointing. However, recent preclinical and phase I/II clinical studies using a novel, oral, reversible CDK4/6 inhibitor, palbociclib (PD-0332991), have validated the role of CDK4/6 as a potential target in estrogen receptor-positive (ER+) breast cancers. This review highlights our current understanding of CDK signaling in both normal and malignant breast tissues, with special attention placed on recent clinical advances in inhibition of CDK4/6 in ER+ disease.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

cancer, cdk, breast, pubmed, article, cell, cyclin, google, scholar, cas, cycle, phase, inhibitors, clinical, kinase, palbociclib, patients, central, activity, study, cancers, cyclindependent, studies, inhibition, data, development, inhibitor, advanced, combination, dcdk, letrozole, signaling, treatment, role, human, prb, response, months, kinases, disease, preclinical, cells, cdks, estrogen, tumor, biol, res, results, specific, research,

Topics {✒️}

/press-release/pfizers-palbociclib-pd-0332991-receives-food gov/newsevents/newsroom/pressannouncements/ucm432871 hematopoietic stem/progenitor cells advanced estrogen receptor-positive thyroid hormone receptor-β s-phase-specific target genes article download pdf muscle stem cells cyclin-dependent kinases regulate x-ray crystallographic structures post-menopausal breast cancer x-ray crystallographic studies cyclin-dependent kinase pathways allowed pre-menopausal women serine/threonine protein kinases anti-cancer drug flavopiridol cyclin d-dependent kinases advanced post-menopausal er+ heavily pre-treated cohort neu-induced breast tumorigenesis her2-amplified breast cancers her2-negative breast cancer cyclin-dependent kinase inhibitor estrogen receptor-positive short-lived cell cycle heavily pre-treated patients drug-administration-breakthrough-ther p130-e2f4 complexes characteristic significant single-agent activity classic pan-cdk inhibitor cyclin-dependent kinase phosphorylation emerging biological therapies her2-amplified cell models family cyclin-dependent kinases hormone receptor-positive hormone receptor positive preferentially inhibits proliferation compare progression-free survival peptide growth factor oestrogen receptor-positive //breast-cancer-research pure g1 arrest enhanced p27kip1 activity comprehensive molecular portraits human breast cancer advanced prb + solid tumors metastatic post-menopausal temperature-sensitive yeast mutants cancer research program mammalian cells cycle

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
         description:Despite significant advances in early detection and treatment, breast cancer still remains a major cause of morbidity and mortality for women. Our understanding of the molecular heterogeneity of the disease has significantly expanded over the past decade and the role of cell cycle signaling in both breast cancer oncogenesis and anti-estrogen resistance has gained increasing attention. The mammalian cell cycle is driven by a complex interplay between cyclins and their associated cyclin-dependent kinase (CDK) partners, and dysregulation of this process is one of the hallmarks of cancer. Despite this, initial results with broadly acting CDK inhibitors were largely disappointing. However, recent preclinical and phase I/II clinical studies using a novel, oral, reversible CDK4/6 inhibitor, palbociclib (PD-0332991), have validated the role of CDK4/6 as a potential target in estrogen receptor-positive (ER+) breast cancers. This review highlights our current understanding of CDK signaling in both normal and malignant breast tissues, with special attention placed on recent clinical advances in inhibition of CDK4/6 in ER+ disease.
         datePublished:2016-02-09T00:00:00Z
         dateModified:2016-02-09T00:00:00Z
         pageStart:1
         pageEnd:11
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s13058-015-0661-5
         keywords:
            Breast Cancer
            Letrozole
            Fulvestrant
            Flavopiridol
            Clinical Benefit Rate
            Cancer Research
            Oncology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13058-015-0661-5/MediaObjects/13058_2015_661_Fig1_HTML.gif
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:18
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Richard S. Finn
               affiliation:
                     name:Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology Oncology
                     address:
                        name:Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology Oncology, Santa Monica, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Alexey Aleshin
               affiliation:
                     name:Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology Oncology
                     address:
                        name:Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology Oncology, Santa Monica, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dennis J. Slamon
               affiliation:
                     name:Stanford School of Medicine
                     address:
                        name:Stanford School of Medicine, Stanford, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
      description:Despite significant advances in early detection and treatment, breast cancer still remains a major cause of morbidity and mortality for women. Our understanding of the molecular heterogeneity of the disease has significantly expanded over the past decade and the role of cell cycle signaling in both breast cancer oncogenesis and anti-estrogen resistance has gained increasing attention. The mammalian cell cycle is driven by a complex interplay between cyclins and their associated cyclin-dependent kinase (CDK) partners, and dysregulation of this process is one of the hallmarks of cancer. Despite this, initial results with broadly acting CDK inhibitors were largely disappointing. However, recent preclinical and phase I/II clinical studies using a novel, oral, reversible CDK4/6 inhibitor, palbociclib (PD-0332991), have validated the role of CDK4/6 as a potential target in estrogen receptor-positive (ER+) breast cancers. This review highlights our current understanding of CDK signaling in both normal and malignant breast tissues, with special attention placed on recent clinical advances in inhibition of CDK4/6 in ER+ disease.
      datePublished:2016-02-09T00:00:00Z
      dateModified:2016-02-09T00:00:00Z
      pageStart:1
      pageEnd:11
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s13058-015-0661-5
      keywords:
         Breast Cancer
         Letrozole
         Fulvestrant
         Flavopiridol
         Clinical Benefit Rate
         Cancer Research
         Oncology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13058-015-0661-5/MediaObjects/13058_2015_661_Fig1_HTML.gif
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:18
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Richard S. Finn
            affiliation:
                  name:Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology Oncology
                  address:
                     name:Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology Oncology, Santa Monica, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Alexey Aleshin
            affiliation:
                  name:Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology Oncology
                  address:
                     name:Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology Oncology, Santa Monica, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dennis J. Slamon
            affiliation:
                  name:Stanford School of Medicine
                  address:
                     name:Stanford School of Medicine, Stanford, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:18
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology Oncology
      address:
         name:Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology Oncology, Santa Monica, USA
         type:PostalAddress
      name:Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology Oncology
      address:
         name:Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology Oncology, Santa Monica, USA
         type:PostalAddress
      name:Stanford School of Medicine
      address:
         name:Stanford School of Medicine, Stanford, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Richard S. Finn
      affiliation:
            name:Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology Oncology
            address:
               name:Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology Oncology, Santa Monica, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Alexey Aleshin
      affiliation:
            name:Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology Oncology
            address:
               name:Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology Oncology, Santa Monica, USA
               type:PostalAddress
            type:Organization
      name:Dennis J. Slamon
      affiliation:
            name:Stanford School of Medicine
            address:
               name:Stanford School of Medicine, Stanford, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology Oncology, Santa Monica, USA
      name:Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology Oncology, Santa Monica, USA
      name:Stanford School of Medicine, Stanford, USA

External Links {🔗}(276)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.26s.

LINK . SPRINGER . COM {}